Rivermark Medical
Rivermark Medical is dedicated to redefining benign prostatic hyperplasia (BPH) treatment through innovative solutions. Led by practicing urologist Adam Kadlec, the company creates clinically grounded medical devices aimed at improving patient care. Their flagship product, FloStent, is a minimally invasive device designed to restore urinary flow and preserve treatment options, currently in development and clinical trials.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Minimally invasive nitinol urethral implant system
A small implantable nitinol device and compatible delivery system designed to be placed via cystoscopy to relieve symptoms of benign prostatic hyperplasia while preserving future treatment options.
Minimally invasive nitinol urethral implant system
A small implantable nitinol device and compatible delivery system designed to be placed via cystoscopy to relieve symptoms of benign prostatic hyperplasia while preserving future treatment options.
Services
Enrollment of qualified patients into investigational device studies with study-related care provided and compensation for time and travel associated with scheduled study visits.
Training and certification of urologists to perform the implant procedure, including proctoring of procedures within clinical studies or early commercial use.
Enrollment of qualified patients into investigational device studies with study-related care provided and compensation for time and travel associated with scheduled study visits.
Training and certification of urologists to perform the implant procedure, including proctoring of procedures within clinical studies or early commercial use.
Expertise Areas
- Benign prostatic hyperplasia (BPH) device therapy
- Clinical trial management for implantable urology devices
- Office-based urological procedure workflows
- Medical device design and engineering
Key Technologies
- Nitinol-based implantable devices
- Cystoscopic delivery systems
- Minimally invasive urological implant procedures
- Randomized multicenter clinical trial methodologies
News & Updates
Rivermark Medical announced the enrollment of the first patient in its RAPID III clinical study, a trial to evaluate the safety and effectiveness of the FloStent™ System in men with BPH.
The company closed a Series C financing to fund further development of the FloStent system, aiming to provide immediate relief for BPH patients.
The company completed its RAPID-UR study evaluating FloStent in patients with urinary retention due to BPH.
Rivermark Medical Announces Successful First-in-Human Use of its Flostent System for Symptomatic BPH
First-in-human procedures performed on 15 patients to evaluate delivery, safety, and effectiveness of FloStent.
Rivermark Medical Announces Fully Enrolled Multi-center OUS Clinical Trial for Innovative BPH Device
Full enrollment of the RAPID-II trial across sites in Australia, New Zealand, and Mexico.
Rivermark Medical announced the enrollment of the first patient in its RAPID III clinical study, a trial to evaluate the safety and effectiveness of the FloStent™ System in men with BPH.
The company closed a Series C financing to fund further development of the FloStent system, aiming to provide immediate relief for BPH patients.
The company completed its RAPID-UR study evaluating FloStent in patients with urinary retention due to BPH.
Rivermark Medical Announces Successful First-in-Human Use of its Flostent System for Symptomatic BPH
First-in-human procedures performed on 15 patients to evaluate delivery, safety, and effectiveness of FloStent.
Rivermark Medical Announces Fully Enrolled Multi-center OUS Clinical Trial for Innovative BPH Device
Full enrollment of the RAPID-II trial across sites in Australia, New Zealand, and Mexico.